%0 Journal Article
%T Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study.
%A Feng T
%A Li J
%A Wu L
%A He X
%A Ye J
%J BMC Pulm Med
%V 24
%N 1
%D 2024 Jul 30
%M 39080576
%F 3.32
%R 10.1186/s12890-024-03182-8
%X <B>BACKGROUND: </B>Hepatic steatosis and its related complications are risk factors for multiple respiratory diseases; however, the causal relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and pulmonary function remains controversial. We aimed to identify it using a national cohort and Mendelian randomization (MR).<BR><B>METHODS: </B>We enrolled 30,442 participants from the 2007 to 2012 National Health and Nutrition Examination Survey. Demographics, pulmonary function indices (forced expiratory volume in 1 s [FEV1], forced vital capacity [FVC]), and variables used to calculate the liver fat score (LFS) were collected. A two-sample MR analysis employing the summary data of genome-wide association studies on MASLD and FEV1/FVC, chronic obstructive pulmonary disease (COPD), and asthma from the Finngen Biobank and Medical Research Council Integrative Epidemiology Unit was performed.<BR><B>RESULTS: </B>A total of 3,462 participants, 1,335 of whom had MASLD (LFS > -0.640), were finally included in the study. The FEV1 (3,204.7 vs. 3,262.5 ml, P = 0.061), FVC (4,089.1 vs. 4,143.8 ml, P = 0.146), FEV1/FVC ratio (78.5% vs. 78.8%, P = 0.233), and FEV1/predicted FEV1 ratio (146.5% vs. 141.7%, P = 0.366) were not significantly different between people with MASLD and those without. Additionally, the MR analysis suggested no causal correlation between MASLD and FEV1/FVC (P = 0.817), MASLD and COPD (P = 0.407), and MASLD and asthma (P = 0.808). Reverse MR studies showed no causal relationships yet (all P > 0.05).<BR><B>CONCLUSIONS: </B>Our study provides convincing evidence that there is no causal association between MASLD and pulmonary function.